{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T20:25:55Z","timestamp":1768940755596,"version":"3.49.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This retrospective analysis aims to explore the risk of chronic kidney disease (CKD) among type 2 diabetes mellitus (DM) patients with different scores of adapted diabetes complications severity index (DCSI) who received sodium-glucose cotransporter-2 inhibitors (SGLT2Is).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study includes 113,449 DM patients from the Taiwan National Health Insurance Research Database (NHIRD). We analyzed the data collected from 107,440 patients showing a DCSI score change of\u2009&amp;lt;\u20091 per year, 3720 patients with a score change of 1 to 2 per year and 2289 patients with a score change of\u2009&amp;gt;\u20092 per year. Cox proportional hazard models were used to evaluate the CKD risk throughout the overall follow-up period, and were adjusted for sex, age, comorbidities and medications of a-glucosidase inhibitors, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, biguanides, dipeptidyl peptidase-4\u00a0inhibitors, glucagon like peptide-1 receptor agonists, insulin, meglitinides, sulphonylurea and thiazolidinedione.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The incidence of CKD increased from 18.30 per 1000 person-years in patients with a score change of\u00a0&amp;lt;\u00a01 per year to 137.55 per 1000 person-years for those with a score change of\u2009&amp;gt;\u20092 per year. Patients with a higher score change (&amp;gt;\u20092 per year) and receiving SGLT2Is had a lower risk of developing CKD than patients who did not receive SGLT2Is.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The use of SGLT2Is was significantly associated with the reduction in CKD incidence in diabetic patients with a higher DCSI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-022-01522-7","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T03:03:08Z","timestamp":1671418988000},"page":"713-718","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Role of sodium-glucose cotransporter-2 inhibitors in risk of chronic kidney disease among patients with type 2 diabetes mellitus"],"prefix":"10.1093","volume":"36","author":[{"given":"Tung-Sheng","family":"Chen","sequence":"first","affiliation":[{"name":"School of Life Science, National Taiwan Normal University, Taipei, Taiwan 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teng-Shun","family":"Yu","sequence":"additional","affiliation":[{"name":"Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Li","family":"Lin","sequence":"additional","affiliation":[{"name":"Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung Y.","family":"Hsu","sequence":"additional","affiliation":[{"name":"Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung, Taiwan 3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Syun","family":"Hu","sequence":"additional","affiliation":[{"name":"School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan 4"},{"name":"Division of Cardiovascular Medicine, Department of Medicine, China Medical University Hospital, 2, Yuh-Der Road, 40447, Taichung, Taiwan 5"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"2026012001323090100_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1136\/bmj.g4356","article-title":"Guideline Development Group Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance","volume":"349","author":"Rabar","year":"2014","journal-title":"BMJ"},{"issue":"25","key":"2026012001323090100_CR2","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002 24239923","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol."},{"issue":"15","key":"2026012001323090100_CR3","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190 32865377","article-title":"EMPEROR-reduced trial investigators cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med."},{"issue":"5","key":"2026012001323090100_CR4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/ejhf.1432 30895697","article-title":"DAPA-HF Committees and Investigators A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail."},{"issue":"1","key":"2026012001323090100_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12933-020-01163-9 33222693","article-title":"Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk","volume":"19","author":"Giorgino","year":"2020","journal-title":"Review Cardiovasc Diabetol"},{"key":"2026012001323090100_CR6","first-page":"9","article-title":"Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease","volume":"19","author":"Bailey","year":"2022","journal-title":"Curr Diab Rep."},{"key":"2026012001323090100_CR7","first-page":"2","article-title":"Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review","volume":"2","author":"Fonseca-Correa","year":"2021","journal-title":"Front Med"},{"issue":"2","key":"2026012001323090100_CR8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/MNH.0000000000000584 31815757","article-title":"Renal effects of SGLT2 inhibitors: an update","volume":"29","author":"Nespoux","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026012001323090100_CR9","doi-asserted-by":"publisher","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013 24226524","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026012001323090100_CR10","doi-asserted-by":"publisher","first-page":"F767","DOI":"10.1152\/ajprenal.00565.2018","article-title":"Empagliflozin attenuates diabetictubulopathy by improving mitochondrial fragmentation and autophagy","volume":"317","author":"LeeYH Kim","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026012001323090100_CR11","first-page":"15","article-title":"Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization","volume":"14","author":"Young","year":"2008","journal-title":"Am J Manag Care"},{"key":"2026012001323090100_CR12","first-page":"721","article-title":"Validating the adapted diabetes complications severity index in claims data","volume":"18","author":"Chang","year":"2012","journal-title":"Am J Manag Care"},{"issue":"8","key":"2026012001323090100_CR13","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1002\/clc.22991 29896758","article-title":"Use of the progression of adapted Diabetes Complications Severity Index to predict acute coronary syndrome, ischemic stroke, and mortality in Asian patients with type 2 diabetes mellitus: a nationwide cohort investigation","volume":"41","author":"Hu","year":"2018","journal-title":"Clin Cardiol"},{"issue":"269","key":"2026012001323090100_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijcard.2018.07.010","article-title":"Comparisons of changes in the adapted diabetes complications severity index and CHA2DS2-VASc score for atrial fibrillation risk stratification in patients with type 2 diabetes mellitus: A nationwide cohort study","volume":"15","author":"Hu","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026012001323090100_CR15"},{"key":"2026012001323090100_CR16","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/pds.2087 21351304","article-title":"Validation of the national health insurance research database with ischemic stroke cases in Taiwan","volume":"20","author":"Cheng","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"2026012001323090100_CR17","doi-asserted-by":"publisher","first-page":"500","DOI":"10.2188\/jea.JE20140076 25174915","article-title":"Validation of acute myocardial infarction cases in the national health insurance research database in Taiwan","volume":"24","author":"Cheng","year":"2014","journal-title":"J Epidemiol"},{"key":"2026012001323090100_CR18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijcard.2015.07.075 26292275","article-title":"Validity of in-hospital mortality data among patients with acute myocardial infarction or stroke in National Health Insurance Research Database in Taiwan","volume":"201","author":"Cheng","year":"2015","journal-title":"Int J Cardiol"},{"key":"2026012001323090100_CR19","first-page":"2","article-title":"Risk factors for chronic kidney disease: an update","volume":"2013","author":"Kazancio\u011flu","year":"2011","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"2026012001323090100_CR20","doi-asserted-by":"publisher","first-page":"648","DOI":"10.2215\/CJN.07830520 33177074","article-title":"CRIC Study Investigators Chronic Renal Insufficiency Cohort (CRIC) Study Investigators Risk factors for CKD progression: overview of findings from the CRIC study","volume":"16","author":"Hannan","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"2026012001323090100_CR21","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s11739-019-02089-1 31073825","article-title":"Comparison of incidence of acute kidney injury, chronic kidney disease and end-stage renal disease between atrial fibrillation and atrial flutter: real-world evidences from a propensity score-matched national cohort analysis","volume":"14","author":"Hu","year":"2019","journal-title":"Intern Emerg Med"},{"issue":"1","key":"2026012001323090100_CR22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1053\/j.ajkd.2020.08.003 33121838","article-title":"SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the national kidney foundation","volume":"77","author":"Tuttle","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2026012001323090100_CR23","first-page":"59","article-title":"Use of SGLT-2 inhibitors in patients with chronic kidney disease","volume":"70","author":"Mottl","year":"2021","journal-title":"J Fam Pract."},{"issue":"3","key":"2026012001323090100_CR24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.34067\/KID.0007862021","article-title":"Prescribing patterns of sodium-glucose cotransporter-2 inhibitors in patients with CKD: a cross-sectional registry analysis","volume":"3","author":"Zhuo","year":"2022","journal-title":"Kidney"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-022-01522-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-022-01522-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/36\/3\/713\/66016743\/joneph_36_3_1522.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-022-01522-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/36\/3\/713\/66016743\/joneph_36_3_1522.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:32:38Z","timestamp":1768890758000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/36\/3\/713\/8307300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,12,19]]},"published-print":{"date-parts":[[2023,4,1]]}},"URL":"https:\/\/doi.org\/10.1007\/s40620-022-01522-7","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2022,12,19]]},"assertion":[{"value":"16 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Institutional Review Board (IRB) of China Medical University (CMUH110-REC1-038(CR-1)) has approved this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}